1 **Risk of venous thromboembolism following hemorrhagic fever with renal syndrome:**

2 **A self-controlled case series study**

3

4 Anne-Marie Connolly-Andersen[1]*, Heather Whitaker[2], Jonas Klingström[3], Clas Ahlm[1]

5

6 1. Unit of Infectious Diseases, Dept. of Clinical Microbiology, Umeå University, Umeå,

7 Sweden

8 2. Dept. of Mathematics and Statistics, The Open University, Milton Keynes, U.K.

9 3. Centre for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska

10 University Hospital, Stockholm, Sweden

11

12 * Corresponding author:

13 Anne-Marie Connolly-Andersen, PhD

14 Division of Infectious Diseases, Dept. of Clinical Microbiology, Umeå University

15 901 85 Umeå, Sweden

16 Telephone: +46 90 7850921, Fax +46-90-133006

17 Email: anne-marie.connolly-andersen@umu.se

18

21

22 **Running title:** HFRS and venous thromboembolism risk

23

24 **Summary:** The risk of venous thromboembolism is significantly increased following

25 hemorrhagic fever with renal syndrome and is higher in females compared to males. Our

26   study is the first to determine the risk of venous thromboembolism following a viral

27   hemorrhagic fever.

28

29   Word count

30   Manuscript: 2360

31   Abstract: 242

32 **Abstract**

33 **Background:** Bleeding is associated with viral hemorrhagic fevers; however,

34 thromboembolic complications has received less attention. Hemorrhagic fever with renal

35 syndrome (HFRS) is a mild viral hemorrhagic fever caused by Puumala hantavirus. We

36 previously identified HFRS as a risk factor for myocardial infarction and stroke, but the risk

37 for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary

38 embolism (PE) is unknown.

39 **Methods:** Personal identity numbers from the Swedish HFRS database were cross-linked

40 with the Patient Register to obtain information on all causes for hospitalization during 1964 to

41 2013. The self-controlled case series method was used to calculate the incidence rate ratio

42 (IRR) for first VTE, DVT and PE during 1998 to 2013.

43 **Results:** From 7 244 patients with HFRS, there were 146 with a first VTE of which 74 were

44 DVT and 78 were PE, and 6 patients had both DVT and PE. The overall risk for a VTE was

45 significantly higher during the first two weeks following HFRS onset with IRR 61.8 and 95%

46 confidence interval (CI) 34.7-110.2. The corresponding risk for a DVT was 45.9 (17.2-118.5)

47 and PE 72.7 (34.9-151.2). Sex interacted significantly with the association between HFRS and

48 VTE, with females having a higher risk compared to males.

49 **Conclusion:** A significantly increased risk for VTE was found in the time period following

50 HFRS onset. It is important to keep this in mind and monitor HFRS patients, and possibly

51 other viral hemorrhagic fever patients, for early symptoms of VTE.

Introduction

Viral hemorrhagic fever contains members from four viral families: *Bunyaviridae*, *Filoviridae*, *Arenaviridae* and *Flaviviridae*. Pathogenic hantaviruses from the *Bunyaviridae* family cause hantavirus cardiopulmonary syndrome in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia, and recently hantaviruses have also been reported from Africa [1]. Annually, over 100 000 cases of hantavirus infections are estimated to be diagnosed worldwide [1]. Puumala hantavirus causes HFRS and is a mild viral hemorrhagic fever endemic in Central and Northern Europe [2]. HFRS is a disease characterized by endothelial and platelet activation, coagulation disturbances and renal dysfunction [1, 3-6]. Endothelial dysfunction and hypercoagulability are common during viral hemorrhagic fever, which are risk factors for thromboembolism [2, 7, 8]. Recently, HFRS was identified as a risk factor for the arterial thromboembolic events: acute myocardial infarction (AMI) and stroke [9]. However, no studies have focused on the risk for venous thromboembolism (VTE) following a viral hemorrhagic fever. Therefore, the present study determined the risk of VTE occurrence in a large cohort of patients with HFRS.

4

Methods

Subject and data sources

HFRS is a notifiable disease in Sweden; therefore, the Public Health Agency of Sweden registers all HFRS diagnosed individuals by their personal identity number (PIN). Every Swedish citizen is issued a PIN at birth by the Swedish Tax Agency. The diagnosis of HFRS is confirmed by detection of specific IgM and/or IgG seroconversion using an indirect immunofluorescence method or ELISA in accredited laboratories, as previously described [9]. The data reported into the HFRS database includes dates of HFRS onset, sample date, diagnosis and reporting as previously reported by us [9]. Data on venous thromboembolism (VTE) and date of HFRS onset were obtained by crosslinking the HFRS database with the inpatient register (IPR), Cause of Death Register and Outpatient Register using the PIN for each patient. All data were anonymized by the Swedish National Board of Health and Welfare. The first VTE (including deep vein thrombosis (DVT) and pulmonary embolism (PE)) was identified between 1964 through 2013 using ICD7 through ICD10 (see Supplementary Table 1 for ICD codes). It is only possible to calculate the risk of a VTE following HFRS onset after 1997 (where the disease became notifiable). But since the self-controlled case series method requires a full exposure risk history (364 days from HFRS) prior to initiation of the study period only individuals with a first VTE during 1998 to 2013 were included. Ethical approval was granted by the Regional Ethical Board of Stockholm, Sweden.

Study design and statistical analysis

The incidence rate ratio (IRR) and 95% confidence interval (CI) of venous and/or arterial thromboembolism during risk periods following HFRS onset compared with control periods was determined using the self-controlled case series method. The risk period was divided into

92   weeks following HFRS disease onset: 1-2, 3-4, 5-8, 9-12, 13-26 and 27-52 weeks (or for

93   follow-up studies: 1-4, 5-8, 9-12 and 13-52 weeks). Exposure to the virus is unlikely in the

94   immediate time period following VTE due to hospitalization and recovery. In addition, HFRS

95   diagnosis may be delayed [9]. We therefore excluded the 26 weeks prior to HFRS disease

96   onset to allow for these factors. The control period spanned the period 1st of January 1998

97   until 31st December 2013 or date of death, excluding the 26-week pre-exposure buffer period

98   and the risk period (see Figure 1). Patients with VTE as the cause of death at the time of event

99   were excluded to meet the assumptions of the self-controlled case series method [10].

100   All models adjusted for age using the age groups: 0-49; 50-59; 60-69; 70-79 and > 80 years of

101   age at thromboembolism event, since the incidence of VTE increases with age [11, 12]. A

102   likelihood ratio test was applied to examine the interactions between sex or seasonality and

103   VTE risk following HFRS onset. Seasons were divided into colder months: October through

104   March and warmer months: April through September. Median ages were compared using non-

105   parametric Mann-Whitney test. Gender distribution was compared using χ^2 test.

106   Sensitivity analyses were run excluding individuals with other known risk factors for VTE:

107   cancer, surgery or hospitalization for any reason 6 weeks prior to the event and the age-

108   adjusted IRR for VTE following HFRS was calculated separately [11, 12]. The cancer

109   diagnoses codes were as follows: ICD-7 codes 140-239; ICD-8 codes 140-239; ICD-9 codes

110   140-239 and ICD-10 codes C00-D48. Two separate analyses were performed where

111   individuals diagnosed with cancer were excluded. The first analysis excluded individuals with

112   diagnosis of cancer at any time point of their life regardless when the VTE occurred. The

113   second analysis excluded only individuals with a cancer diagnosis within ± 12 months of VTE

114   event.

115   We analyzed whether the length of hospitalization differed between the control period

116   (including buffer period) and the risk period, thereby predisposing to VTE, using the non-

117   parametric Mann-Whitney U-test. Since anti-coagulation treatment indicates other risk factors

118   and affects the coagulation system, individuals on anti-coagulation therapy prior to event were

119   excluded in a follow-up analysis and the IRR for VTE following HFRS calculated. These

120   patients were identified using the ICD-10 code Z921 (long-term usage of anti-coagulants in

121   personal history); anatomical therapeutic chemical (ATC) code: B01AA03 (warfarin) or

122   B01AB04 (fragmin); atrial fibrillation or heart valve prosthesis of non-biological origin (ICD-

123   7: 433.12 and 433.13; ICD-8: 427.92 and 427.90; ICD-9: 427D, 427A and V43D; and ICD-

124   10: I48 or Z952).

125   Statistical analyses of date were performed using SPSS (version 24) or Stata (version 12.0

126   SE). All P-values are 2-sided and $P < 0.05$ is considered statistically significant.

Results

From 1997 where HFRS became a notifiable disease, there were a total of 7 244 patients

registered in The HFRS database up to 2014. From these patients, that were diagnosed with

HFRS from 1997, 6 435 (88.8%) were hospitalized for any cause during 1964-2013 (IPR).

2 663 (36.8%) were hospitalized due to HFRS (IPR) either as the main or contributing cause

of hospitalization. 483 (6.7%) had deceased during 1997-2013 (Cause of Death register).

During 1998 to 2013 there were 146 HFRS patients with a first VTE (2%). Of these, 34

patients (23%) had their first VTE during our specified risk period (0-52 weeks following

HFRS onset).

The baseline demographics and the number of individuals with known risk factors for VTE

are shown in Table 1. Generally, the individuals in the study groups were older compared to

the HFRS cohort. In addition, the sex distribution differed significantly between the PE study

group compared to the HFRS cohort (Table 1).

Venous thromboembolism following HFRS onset

The IRR for a first VTE was significantly increased in the first half year (apart from 9-12

weeks) following HFRS (Table 2) compared to the control period. VTE was further divided

into DVT and PE, where the IRR for DVT was significantly increased the first year following

HFRS. The IRR for PE was significantly higher in the first month only following HFRS. The

IRR for PE in the first two weeks following HFRS was higher than that for DVT. Sex had a

significant modifying effect on the association between HFRS and VTE (Supplementary

Table 2). The IRR for VTE for females was higher compared to males in the four weeks

following HFRS onset. Similarly, the risks for DVT and PE were higher in females compared

to males in the same time period. Season did not have a confounding effect on VTE

(Supplementary Table 2). Other risk factors for VTE include cancer diagnosis, surgery and

152   immobilization [11, 12]. However, the association between HFRS and VTE was still

153   significant even after excluding individuals who had had a cancer diagnosis at 1) any time

154   point during the observation period or 2) within ± 12 months of HFRS (Supplementary

155   Table3). The association between HFRS and VTE was still significant even after excluding

156   individuals who had undergone surgery or were hospitalized for any reason 6 weeks prior to

157   HFRS, respectively (Supplementary Table 3). In addition, anti-coagulation treatment could

158   attenuate the association between HFRS and VTE. Yet, the association was similar even after

159   these individuals were excluded (Supplementary Table 3). Another risk factor for VTE is

160   immobilization. If patients are hospitalized for a longer time during HFRS (risk period)

161   compared to hospitalizations during the control period, this could predispose to VTE [11, 12].

162   We did not find a significant difference in the length of hospitalization in the control period

163   vs. the risk period (see Supplementary Table 4).

Discussion

This study of all Swedish HFRS patients from 1997 to 2014 determines an increased risk for venous thromboembolism following a viral hemorrhagic fever. We previously identified HFRS as a risk factor for acute myocardial infarction and stroke [9].

We found a statistically significant modifying effect of sex on the association between HFRS and VTE with females having a higher IRR for a first VTE compared to males. Furthermore, though the IRRs for females were higher, the length of time with increased risk for VTEs following HFRS onset was longer in males. Only one female under 59 years of age had VTE during the risk period indicating that reproductive risk factors are not an explanation for our results. The cytokine profile differs between males and females during acute HFRS, whether this translates into an increased risk for VTE is unknown [13]. Other risk factors for VTE include cancer, surgery and immobilization (hospitalization) [11, 14] and a protective factor is anti-coagulants, though when we performed sensitivity analyses including these factors, they did not modify our results.

Previous studies have associated infections with increased risk for VTE [15-17] . In a study with a similar methodology to ours, the risk for a DVT and PE was increased approximately two-fold in the first two weeks following a urinary tract infection and similarly for DVT following a systemic respiratory tract infection.[15]. Notably, we observe in our study of HFRS patients a much higher risk for DVT ($\approx$ 46-fold) and PE ($\approx$ 73-fold) in the same period, indicating the potency of the interaction between hantaviral infection, the endothelium and the coagulation system. Our results are further supported by autopsies of patients who died due to Puumala hantavirus infection, who had thromboses in pulmonary vessels [18]. That HFRS patients have coagulopathy is indicated by almost one-third of HFRS patients fulfilling

189   criteria for disseminated intravascular coagulation [5], increased platelet activation during

190   HFRS [4], deregulated fibrinolysis [6] and the identification of HFRS as a risk factor for the

191   two specific cardiovascular events AMI and stroke [9]. Endothelial cells are a key player in

192   VHF pathogenesis and clinical outcome [19], and hantaviruses target endothelial cells during

193   infection resulting in increased coagulation and platelet adhesion [20]. Furthermore, the

194   increased risk for arterial and venous thromboembolism during HFRS, as shown in our

195   previous and current study, indicates that endothelial cells are affected during hantaviral

196   infection regardless of their location [9]. Thereby there are several mechanisms during

197   hantavirus infection that could explain the increased risk for thromboembolism that we show

198   in this cohort based study.

199   Concerning other viral hemorrhagic fevers, case reports for Dengue virus indicate a similar

200   tendency for venous thromboembolism that we observed in our study [21]. Also, thrombosis

201   is relevant for the outcome in viral hemorrhagic fever, which was indicated in a study where

202   increased von Willebrand factor levels in patients with hemorrhagic manifestations following

203   infection with Sudan ebolavirus led to speculation that these patients have excessive

204   thrombosis [22]. In addition, case reports of two other ebolavirus infected patients indicated a

205   hypercoagulable phase following infection that warranted treatment with low-molecular-

206   weight heparin [23]. However, the risk for thromboembolism following these viral

207   hemorrhagic fevers has yet to be determined and quantified.

208

209   A strength of our study is that it comprises all individuals in Sweden with verified HFRS

210   since 1997 until 2014. In addition, we have data from the IPR since 1964, with complete

211   coverage from 1987 [24]. We could therefore identify the first venous thromboembolic event

212   with high precision from 1987 up until 2013.

213   The self-controlled case series method requires precision of the exposure date (HFRS disease

214   onset), since the method is sensitive to timing and dates [10]. For nearly 80% of our patients,

215   we have the actual date of HFRS disease onset, which is another strength of our study. The

216   least accurate date, the date of report to the Public Health Agency of Sweden, constitutes only

217   0.7% of the dates. However, in order to circumvent potential imprecision of HFRS disease

218   onset, we included a 6-month buffer prior to the HFRS date. This ensures that a patient who

219   receives a delayed HFRS diagnosis or registration date with venous thromboembolism during

220   that delay period, will not affect the actual IRR for a thromboembolism.

221

222   A limitation of this study is that we do not have access to information regarding whether the

223   individuals are on systemic hormone replacement therapy, use oral contraceptives or are

224   pregnant since these are risk factors for VTE [11, 14].

225   In Sweden, the IPR has been extensively validated concerning the codes for AMI and stroke

226   diagnoses but not for VTE [24]. There is a potential risk for a less accuracy and over- or

227   underestimation of VTE events, which is a limitation of our study. However, that risk should

228   equally apply to both the control period and the risk period. Thereby the probability of it

229   affecting the IRR following HFRS is likely low.

230   An additional limitation is that although we did not find a significant difference in the length

231   of hospitalization between the control periods compared to the risk period, the association

232   between HFRS and VTE could still be mediated in part by immobility. Further *in vivo* studies

233   are required to ascertain the link between HFRS and VTE.

234

235   We show a significant but transient association between venous thromboembolism and HFRS.

236   Previous studies show a reduction in venous thromboembolism in patients with infectious

237   disease that were treated with thromboprophylaxis [25]. The Wells score for DVT and PE do

238   not include infectious diseases as a risk factor. A scoring system that takes infectious disease,

239   among others, into account showed a reduction in VTE following identification of high-risk

240   groups with subsequent thromboprophylaxis treatment [26].

241   Our study raises the question whether some patients with HFRS, or other viral hemorrhagic

242   fevers, could potentially benefit from similar thromboprophylaxis in the short-term period.

243   Further clinical studies are warranted to support such recommendations.

256   References

257

258   1.   Avsic-Zupanc T, Saksida A, Korva M. Hantavirus infections. Clin Microbiol Infect **2015**.

259   2.   Chen JP, Cosgriff TM. Hemorrhagic fever virus-induced changes in hemostasis and vascular

260   biology. Blood Coagul Fibrinolysis **2000**; 11(5): 461-83.

261   3.   Connolly-Andersen AM, Thunberg T, Ahlm C. Endothelial activation and repair during

262   hantavirus infection: association with disease outcome. Open forum infectious diseases **2014**;

263   1(1): ofu027.

264   4.   Connolly-Andersen AM, Sundberg E, Ahlm C, et al. Increased Thrombopoiesis and Platelet

265   Activation in Hantavirus-Infected Patients. J Infect Dis **2015**; 212(7): 1061-9.

266   5.   Sundberg E, Hultdin J, Nilsson S, Ahlm C. Evidence of disseminated intravascular

267   coagulation in a hemorrhagic Fever with renal syndrome-scoring models and severe illness.

268   PLoS One **2011**; 6(6): e21134.

269   6.   Laine O, Makela S, Mustonen J, et al. Enhanced thrombin formation and fibrinolysis during

270   acute Puumala hantavirus infection. Thromb Res **2010**; 126(2): 154-8.

271   7.   Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet **2012**;

272   379(9828): 1835-46.

273   8.   Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic

274   cardiovascular events. Thromb Haemost **2010**; 103(1): 56-61.

275   9.   Connolly-Andersen AM, Hammargren E, Whitaker H, et al. Increased risk of acute

276   myocardial infarction and stroke during hemorrhagic fever with renal syndrome: a self-

277   controlled case series study. Circulation **2014**; 129(12): 1295-302.

278   10. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-

279   controlled case series method. Statistics in medicine **2006**; 25(10): 1768-97.

280   11. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein

281   thrombosis: a joint consensus document from the European society of cardiology working

282   groups of aorta and peripheral circulation and pulmonary circulation and right ventricular

283   function. Eur Heart J **2017**.

284   12.   Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and

285   management of acute pulmonary embolism. Eur Heart J **2014**; 35(43): 3033-69, 69a-69k.

286   13.   Klingstrom J, Lindgren T, Ahlm C. Sex-dependent differences in plasma cytokine responses

287   to hantavirus infection. Clin Vaccine Immunol **2008**; 15(5): 885-7.

288   14.   Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and platelets: an update.

289   Eur Heart J **2017**; 38(11): 785-91.

290   15.   Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis

291   and pulmonary embolism after acute infection in a community setting. Lancet **2006**;

292   367(9516): 1075-9.

293   16.   Dalager-Pedersen M, Sogaard M, Schonheyder HC, Thomsen RW, Baron JA, Nielsen H.

294   Venous thromboembolism after community-acquired bacteraemia: a 20-year danish cohort

295   study. PLoS One **2014**; 9(1): e86094.

296   17.   Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Sorensen HT. Acute infections and

297   venous thromboembolism. J Intern Med **2012**; 271(6): 608-18.

298   18.   Rasmuson J, Andersson C, Norrman E, Haney M, Evander M, Ahlm C. Time to revise the

299   paradigm of hantavirus syndromes? Hantavirus pulmonary syndrome caused by European

300   hantavirus. Eur J Clin Microbiol Infect Dis **2011**; 30(5): 685-90.

301   19.   Hepojoki J, Vaheri A, Strandin T. The fundamental role of endothelial cells in hantavirus

302   pathogenesis. Frontiers in microbiology **2014**; 5: 727.

303   20.   Goeijenbier M, Meijers JC, Anfasa F, et al. Effect of Puumala hantavirus infection on human

304   umbilical vein endothelial cell hemostatic function: platelet interactions, increased tissue

305   factor expression and fibrinolysis regulator release. Frontiers in microbiology **2015**; 6: 220.

306   21.   da Costa PS, Ribeiro GM, Junior CS, da Costa Campos L. Severe thrombotic events

307   associated with dengue fever, Brazil. Am J Trop Med Hyg **2012**; 87(4): 741-2.

308   22.   McElroy AK, Erickson BR, Flietstra TD, et al. Von Willebrand factor is elevated in

309   individuals infected with Sudan virus and is associated with adverse clinical outcomes. Viral

310   Immunol **2015**; 28(1): 71-3.

311   23.   Wilson AJ, Martin DS, Maddox V, et al. Thromboelastography in the Management of

312   Coagulopathy Associated With Ebola Virus Disease. Clin Infect Dis **2016**; 62(5): 610-2.

313   24.   Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish

314   national inpatient register. BMC public health **2011**; 11: 450.

315   25.   Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal

316   pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study

317   Group. Lancet **1996**; 347(9012): 1357-61.

318   26.   Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of

319   hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction

320   Score. J Thromb Haemost **2010**; 8(11): 2450-7.

321

322   Figure legends.

323   Figure 1. Study design for analyses of the association between hemorrhagic fever with renal

324   syndrome (HFRS) and venous thromboembolism using the self-controlled case series method.

325   HFRS patients are included from 1st of January 1997 until 30th June 2014. The control period

326   spans the period 1st of January 1998 until 31st December 2013 or date of death, excluding the

327   26-week pre-exposure buffer period and the risk period. The risk period spans 365 days

328   following HFRS disease onset, and is further stratified into 1-2, 3-4, 5-8, 9-12, 13-26 and 27-

329   52 weeks following HFRS onset (or for follow-up studies: 1-4, 5-8, 9-12 and 13-52 weeks

330   following HFRS onset).